CLINICAL & PIPELINE·Drug Approval
FDA Approves Arvinas Operations' VEPPANU (VEPDEGESTRANT) as New Molecular Entity, Reshaping Therapeutic Landscape
Arvinas Operations has secured FDA approval for VEPPANU (VEPDEGESTRANT), a Type 1 New Molecular Entity (NDA219835), on May 1, 2026. This oral tablet, available in 100MG and 200MG strengths, marks a significant market entry. Decision-makers must assess its impact on R&D pipelines, supply chain strategies, and competitive positioning within its target therapeutic area.
90-Day Activity